The persistent and viscous nature of airway secretions in cystic fibrosis disease leads to airway obstruction, opportunistic infection, and deterioration of lung function. 
INTRODUCTION
Cystic fibrosis (CF) is a common lethal genetic disease that results from a mutation in the gene encoding a chloride channel protein, the CF transmembrane conductance regulator. As a result of this defect, epithelia within the body are impermeable to chloride ion transport (4) . Although several organs are affected, including pancreas, intestine, and male genital tract, complications within the lung account for 95% of the morbidity and mortality (35) . In lung, impaired chloride transport into the airway lumen leads to excessive absorption of Na + and fluid, reducing the volume of airway surface liquid (14) . Desiccation of airway surface liquid leads to the concentration of mucin macromolecules, which are the gel forming constituents of mucus (21) . The viscoelastic properties of normal mucus are dependent on the concentration, molecular weight, and entanglements between mucin polymers (34) . Further interaction of mucins with DNA (23, 18, 19) and f-actin polymers (27, 33) released from dying inflammatory cells is responsible for the dense and viscous nature of CF sputum. The inability to clear such mucus by cough or mucociliary clearance worsens lung function and facilitates colonization of the lung with opportunistic pathogens. Chronic lung injury results from a persistent cycle of bacterial infection and inflammatory response.
Despite some promising advances, correction of CF by gene therapy is not yet attainable. Currently, antibiotic regimens, coupled with drugs that facilitate the clearance of purulent airway secretions, remain the mainstay treatments for progressive airway disease. Inhalation of purified rhDNase (Pulmozyme; Genentech, USA), which digests extracellular DNA present in the CF airway, is widely used as a respiratory decongestant.
Such treatment is clinically effective for diminishing sputum viscosity and has some FINAL ACCEPTED VERSION LCMP-0035-2003.R1 4 capacity to improve the forced expiratory volume (FEV) (11) . Other investigative therapies aimed at breaking down mucin or actin polymers, including N-acetylcysteine, nacystelyn (an N-acetyl-L-cysteine derivative), and gelsolin, can also reduce sputum viscosity experimentally, but have yet to attain approval for the application of CF treatment in the United States.
In this investigation, we examined the effects of the Trx reducing system (thioredoxin, thioredoxin reductase, and NADPH) on the physical and rheologic properties of CF sputum in vitro. Thioredoxin (Trx) is a 13-kDa protein containing two redox-active cysteines at its active site (Trp-Cys-Gly -Pro-Cys), which are highly conserved across species. In their oxidized form, these cysteines form a disulfide bridge that protrudes from the three dimensional structure of the protein (12) . Reduction of this active center by the NADPH-dependent thioredoxin reductase (TR) enzyme allows Trx to function as an electron carrier with dithiol/disulfide exchange capability (22) . Protein disulfides are a preferred substrate for Trx-mediated reducing action, and these are readily reduced by Trx with a potency exceeding dithiothreitol (12 Although PAS staining has been useful for the detection of mucin molecules in previous studies, we draw no definitive conclusions regarding the site of action for Trx in sputum, since this assay lacks the capacity to distinguish specific mucin gene products.
Neutrophil lysis within the airways of diseased CF lungs results in the deposition of extracellular DNA into airway secretions (19) . By non-covalent interactions, this DNA becomes entangled within mucin glycoproteins, increasing mucus gel viscoelasticity (26) .
In this study we found that DNA present in sputum becomes increasingly soluble Aliquots of CF sputum were incubated without treatment, with H 2 O, or Trx + reducing system (0.1 µΜ Tr and 2 µM NADPH), at 37 0 C for 20 minutes. All data are presented as log G * (means ± standard error) for 4 samples. Table 2 Trx ( 
